Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,060 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives.
Kongnakorn T, Bharmal M, Kearney M, Phatak H, Benedict A, Bhanegaonkar A, Galsky M. Kongnakorn T, et al. Among authors: kearney m. Clinicoecon Outcomes Res. 2019 Nov 8;11:659-672. doi: 10.2147/CEOR.S215069. eCollection 2019. Clinicoecon Outcomes Res. 2019. PMID: 31807039 Free PMC article.
Treatment Sequencing Patterns in Patients with Metastatic Urothelial Cancer Treated in the Community Practice Setting in the United States: SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR).
Doshi GK, Bhanegaonkar A, Kearney M, Bharmal M, Cislo P, Kim R, Boyd M, Aguilar KM, Phatak H. Doshi GK, et al. Among authors: kearney m. Clinicoecon Outcomes Res. 2020 Nov 5;12:645-656. doi: 10.2147/CEOR.S264942. eCollection 2020. Clinicoecon Outcomes Res. 2020. PMID: 33192078 Free PMC article.
A cost-effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan.
Su PJ, Xiao Y, Lin AY, Goh C, Wu E, Liu K, Chou P, Kuo K, Palencia R, Chang J, Kearney M, Kapetanakis V, Benedict A. Su PJ, et al. Among authors: kearney m. Cancer Rep (Hoboken). 2023 Oct;6(10):e1887. doi: 10.1002/cnr2.1887. Epub 2023 Aug 28. Cancer Rep (Hoboken). 2023. PMID: 37640556 Free PMC article.
Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists' and Urologists' Preferences for First-Line Treatment of Locally Advanced/Unresectable Metastatic Urothelial Carcinoma in Five European Countries.
Panattoni L, Kearney M, Land N, Flottemesch T, Sullivan P, Kirker M, Bharmal M, Hauber B. Panattoni L, et al. Among authors: kearney m. Pharmacoeconomics. 2024 Aug;42(8):895-909. doi: 10.1007/s40273-024-01359-x. Epub 2024 Mar 12. Pharmacoeconomics. 2024. PMID: 38472738
Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France.
Porte F, Granghaud A, Chang J, Kearney M, Morel A, Plessala I, Cawston H, Roiz J, Xiao Y, Solbes MN, Lambert P, Ravaud A, Loriot Y, Thiery-Vuillemin A, Lévy P. Porte F, et al. Among authors: kearney m. PLoS One. 2024 May 10;19(5):e0302548. doi: 10.1371/journal.pone.0302548. eCollection 2024. PLoS One. 2024. PMID: 38728337 Free PMC article.
1,060 results